🚀 VC round data is live in beta, check it out!
Pacific Shuanglin Valuation Multiples
Discover revenue and EBITDA valuation multiples for Pacific Shuanglin and similar public comparables like Innoviva, Faes Farma, Galecto, Nurix Therapeutics and more.
Pacific Shuanglin Overview
About Pacific Shuanglin
Pacific Shuanglin Bio-pharmacy Co Ltd is engaged in the research, development, production, and marketing of blood products.
Founded
1993
HQ
Employees
2.8K
Website
Sectors
Financials (FY)
EV
$2B
Pacific Shuanglin Financials
Pacific Shuanglin reported last fiscal year revenue of $389M and EBITDA of $144M.
In the same fiscal year, Pacific Shuanglin generated $191M in gross profit, $144M in EBITDA, and $109M in net income.
Revenue (LTM)
Pacific Shuanglin P&L
In the most recent fiscal year, Pacific Shuanglin reported revenue of $389M and EBITDA of $144M.
Pacific Shuanglin expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $389M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $191M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 49% | XXX | XXX | XXX |
| EBITDA | — | XXX | $144M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 37% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 30% | XXX | XXX | XXX |
| Net Profit | — | XXX | $109M | XXX | XXX | XXX |
| Net Margin | — | XXX | 28% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Pacific Shuanglin Stock Performance
Pacific Shuanglin has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Pacific Shuanglin's stock price is $1.89.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPacific Shuanglin Valuation Multiples
Pacific Shuanglin trades at 4.5x EV/Revenue multiple, and 12.3x EV/EBITDA.
EV / Revenue (LTM)
Pacific Shuanglin Financial Valuation Multiples
As of April 19, 2026, Pacific Shuanglin has market cap of $2B and EV of $2B.
Equity research analysts estimate Pacific Shuanglin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pacific Shuanglin has a P/E ratio of 16.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 12.3x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 15.0x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 9.3x | XXX | XXX | XXX |
| P/E | — | XXX | 16.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (60.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pacific Shuanglin Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Pacific Shuanglin Margins & Growth Rates
Pacific Shuanglin's revenue in the last fiscal year grew by 14%.
Pacific Shuanglin's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Pacific Shuanglin Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 37% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 16% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Pacific Shuanglin Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Pacific Shuanglin | XXX | XXX | XXX | XXX | XXX | XXX |
| Innoviva | XXX | XXX | XXX | XXX | XXX | XXX |
| Faes Farma | XXX | XXX | XXX | XXX | XXX | XXX |
| Galecto | XXX | XXX | XXX | XXX | XXX | XXX |
| Nurix Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Everest Medicines | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pacific Shuanglin M&A Activity
Pacific Shuanglin acquired XXX companies to date.
Last acquisition by Pacific Shuanglin was on XXXXXXXX, XXXXX. Pacific Shuanglin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Pacific Shuanglin
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPacific Shuanglin Investment Activity
Pacific Shuanglin invested in XXX companies to date.
Pacific Shuanglin made its latest investment on XXXXXXXX, XXXXX. Pacific Shuanglin invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Pacific Shuanglin
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pacific Shuanglin
| When was Pacific Shuanglin founded? | Pacific Shuanglin was founded in 1993. |
| Where is Pacific Shuanglin headquartered? | Pacific Shuanglin is headquartered in China. |
| How many employees does Pacific Shuanglin have? | As of today, Pacific Shuanglin has over 2K employees. |
| Is Pacific Shuanglin publicly listed? | Yes, Pacific Shuanglin is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Pacific Shuanglin? | Pacific Shuanglin trades under 000403 ticker. |
| When did Pacific Shuanglin go public? | Pacific Shuanglin went public in 1996. |
| Who are competitors of Pacific Shuanglin? | Pacific Shuanglin main competitors are Innoviva, Faes Farma, Galecto, Nurix Therapeutics. |
| What is the current market cap of Pacific Shuanglin? | Pacific Shuanglin's current market cap is $2B. |
| What is the current revenue of Pacific Shuanglin? | Pacific Shuanglin's last fiscal year revenue is $389M. |
| What is the current EV/Revenue multiple of Pacific Shuanglin? | Current revenue multiple of Pacific Shuanglin is 4.5x. |
| Is Pacific Shuanglin profitable? | No, Pacific Shuanglin is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.